Skip to main content
Skip to footer

Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

HOME
ABOUT
- Close
- COMPANY OVERVIEW
- MANAGEMENT
- BOARD OF DIRECTORS
AREAS OF FOCUS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
- STORIES
CONTACT US

Main Content

Slide

AKARI THERAPEUTICS IS AN INNOVATIVE TARGETED

ONCOLOGY COMPANY BUILT ON NEXT GENERATION

ANTIBODY-DRUG CONJUGATES (ADC)

CORPORATE PRESENTATION VIEW OUR CORPORATE PRESENTATION

AND A NOVEL DISCOVERY ENGINE

RECENT PRESS RELEASES

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

March 3, 2025

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

February 19, 2025

Akari Therapeutics Joins Webull Corporate Connect Service Platform

February 3, 2025

Akari Therapeutics Announces Key Leadership Appointments

December 18, 2024

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

December 16, 2024

Footer

Follow Us

Privacy Statement

Expanded Access

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.